Semaglutide 7.2mg (Wegovy HD)

Semaglutide 7.2mg, marketed as Wegovy HD and FDA approved in April 2026, represents Novo Nordisk's strategic response to tirzepatide's efficacy challenge. By tripling the dose of the same semaglutide molecule proven in the SELECT trial, Wegovy HD pushes weight loss into territory that previously required dual-receptor agonism. Clinical data show a mean weight loss of 20.7 percent at 72 weeks — closing to within a fraction of tirzepatide's 20.9 percent in SURMOUNT-1 and meaningfully above standard Wegovy's 14.9 percent ceiling. The mechanism remains GLP-1 receptor agonism with the same proven cardiovascular protection profile inherited from the 2.4mg dose, as the SELECT cardiovascular evidence applies to the semaglutide molecule broadly. The drug is administered via once-weekly subcutaneous injection with a modified high-dose pen device, using the same titration philosophy — starting low and escalating gradually — that made the side-effect profile of standard Wegovy manageable for most patients. What makes Wegovy HD particularly notable in May 2026 is its introductory pricing: Novo Nordisk launched it at $149 per month for self-pay patients through August 2026, matching Foundayo's oral pill price and making it the highest-efficacy injectable available at that price point during the introductory window. This pricing is expected to change after August 2026, and patients should confirm current programs before initiating. The nausea and GI side effect profile at the higher dose is being actively characterized in post-market studies, but early clinical experience suggests it aligns with the known semaglutide tolerability profile. Wegovy HD is best suited for patients already on standard semaglutide who have plateaued below their weight loss goal and want to step up within the same molecule rather than switching drug class.